Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunotherapy response in microsatellite-stable poorly differentiated thyroid carcinoma with mismatch repair deficiency and high tumor mutational burden.

Archives of endocrinology and metabolism - 1 Apr 2026

Feldmann João Henrique, Feldmann João Felipe, Hidalgo-Filho Cassio Murilo, Alves Gustavo Luis Contado, Vilela Rafael Sarlo, Gonçalves Sérgio, Castro Júnior Gilberto de

Abstract excerpt

Poorly differentiated thyroid carcinoma (PDTC) is a rare and aggressive malignancy with a poor prognosis. Immunotherapy is typically guided by agnostic biomarkers such as microsatellite instability-high or high tumor mutational burden (TMB); however, these biomarkers are uncommon in PDTC. Therefore, identifying alternative predictive biomarkers remains an urgent necessity. We report the case of a 71-year-old...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ataxia Telangiectasia Mutated Proteins

Share to DNA Mismatch Repair

Share to Immunotherapy

Share to Microsatellite Instability

Share to MutS Homolog 2 Protein

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41649339
DOI: 10.20945/2359-4292-2026-0008
PMCID: PMC12895402

Genes

MSH2
ATM
MSH6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Immunotherapy response in microsatellite-stable poorly differentiated thyroid carcinoma with mismatch repair deficiency and high tumor mutational burden.PMID 41649339Read ↗

Correlation of Mismatch Repair Deficiency with Clinicopathological Features and Programmed Death-Ligand 1 Expression in Thyroid CarcinomaSemantic proximity Read ↗

Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: a case report and literature review.Semantic proximity Read ↗

Predictive Capacity of Mismatch Repair Status in the Use of Immune Checkpoint Inhibitors for the Treatment of Aggressive Pituitary Adenomas and Pituitary Carcinomas: Illustrative Case Report and Literature ReviewSemantic proximity Read ↗

Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiencySemantic proximity Read ↗

The role of temozolomide in the treatment of aggressive pituitary tumors.Semantic proximity Read ↗

Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.Semantic proximity Read ↗

Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.Semantic proximity Read ↗

Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 PatientsSemantic proximity Read ↗

The mismatch repair system is not affected in medullary thyroid carcinoma independent of stromal desmoplasia or ret proto-oncogene mutation.Semantic proximity Read ↗

Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.